Madrigal Pharmaceuticals, Inc.
MDGL
$291.82
$8.963.17%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 50.36% | 47.04% | -8.33% | -77.12% | -91.87% |
| Total Depreciation and Amortization | 158.93% | 155.63% | 120.74% | 111.90% | 35.48% |
| Total Amortization of Deferred Charges | -33.44% | -35.99% | -28.78% | -14.80% | 51.27% |
| Total Other Non-Cash Items | 5.17% | 19.40% | 37.76% | 122.40% | 76.91% |
| Change in Net Operating Assets | -67.65% | -485.42% | 6,100.00% | -597.94% | -17.72% |
| Cash from Operations | 40.40% | -30.72% | 21.12% | -79.19% | -77.43% |
| Capital Expenditure | -- | 81.18% | -129.79% | -89.86% | -920.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 66.53% | 86.77% | -498.93% | -3,229.70% | 152.67% |
| Cash from Investing | 67.13% | 86.76% | -503.18% | -3,171.65% | 152.47% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -98.49% | -95.88% | 60.30% | 378.93% | 3,104.52% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -98.49% | -95.88% | -61.89% | 212.42% | 988.83% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -84.00% | -450.41% | -1,629.83% | -240.39% | 339.46% |